NONOF NOVO NORDISK A/S
- 130.000
- +5.360+4.30%
NOVO NORDISK A/S News
Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024
Novo Nordisk A/S – Reduction of the Share Capital
Weight Loss Drugs and the Many Use Cases in Medical Treatments
Eli Lilly Obesity Therapy Succeeds in Late-stage Trials for Sleep Disorder
GLP-1s Benefit Parkinson's: Barclays Sees Implications Across Biopharma
No Link Between Weight Loss Drugs and Suicidal Thoughts, EU Regulator Concludes
Ginkgo Bioworks Expands R&D Tie-up With Novo Nordisk
Weight-loss Drug Shortage Result of 'Unprecedented Demand'
Certain doses of Eli Lilly's (LLY) GLP-1 weight loss drugs Zepbound and Mounjaro are facing a supply shortage, much like competitor Novo Nordisk's (NVO) own weight-loss treatment Wegovy.
Novo's Ozempic to Face Copycats as Chinese Firm Seeks Approval for Biosimilar
CVS, Elevance Health to Cover Novo Nordisk's Wegovy: WSJ
Altimmune Falls After Q4 Results; Obesity Drug Data Released
Viking Therapeutics Stock Rises on Positive Phase 1 Weight-loss Pill Data
Novo Nordisk Strikes €1bn Deal to Expand Into Heart Disease Treatments
Tesla, Lucid, Novo Nordisk: Trending Tickers
Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease
Wegovy Gains Medicare, Medicaid Coverage for Heart Benefits
Medicare Expands Coverage for Weight Loss Drugs
Awiqli (Once-weekly Basal Insulin Icodec) Recommended for Approval for the Treatment of Diabetes by the European Regulatory Authorities
Medicare Coverage for Obesity Drugs Could Strain Federal Budget: CBO
NASH Drug Market Expected to Surpass $48B by 2035
Analysis
Price Target
No Data
